AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 FEB 6 - (NewsRx.com & NewsRx.net) -- by Sonia Nichols, senior medical writer - An experimental vaccine containing genes for the human papillomavirus 16-L1 (HPV16-L1) protein has shown promising results for halting tumor growth and extending survival in mice.
Researchers say that the plasmid DNA vaccine might be effective for preventing human HPV16 infection, a disease associated with the formation of cervical cancer in women.
According to Leticia Rocha-Zavaleta and associates at the Universidad Nacional Autonoma de Mexcio, Mexico City, the plasmid DNA vaccine worked well when administered either orally, subcutaneously, or intramuscularly to mice, generating sizeable numbers of IgG antibodies against L1.
"Antibodies developed in mice vaccinated subcutaneously were detectable 12 months postimmunization," Rocha-Zavaleta and coworkers stated.
Because HPV infection is a significant risk factor for cervical cancer, researchers were particularly interested in finding out whether antibodies induced by the vaccine could be detected in gynecological tissues. Vaginal washes from immunized mice contained IgA antibodies specific to the viral antigen, according to the investigators.
In challenge experiments where ...
Source: HighBeam Research, DNA Vaccine Expressing Human Papillomavirus Gene Invites Viral...